Akums Drugs & Pharmaceuticals Ltd (AKUMS)
₹754.65
Mkt cap
₹12,052 Cr
P/E ratio
39.50
P/B
3.58
Div yield
0.13%
ROE
8.45%
ROCE
14.90%
EPS (TTM)
₹19.11
Book value
₹211
52W range
414–781
Sector
Healthcare
Price history
Previous close
Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services. [1]
NSE AKUMSBSE 544222
Health check
Constructive
ValuationFair
ProfitabilityAverage
GrowthModerate
TechnicalsBullish
52-week range
−3.32% from high₹755
₹414+82.26% from low₹781
Current
₹754.65
Prev close
₹764.80
Day
−1.33%
Price performance
1D
−1.33%
1W
−2.84%
1M
+8.20%
3M
+37.65%
6M
+61.53%
1Y
+61.66%
YTD
+67.01%
Financials
Revenue, profit & margin
P/E ratio
39.5×
AKUMS is 16% above the sector median of 34.0×
AKUMS39.5×
Sector median34.0×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 970 | 1,181 | 1,083 | 944 | 1,019 | 1,033 | 1,010 | 1,056 | 1,024 | 1,018 | 1,160 | 1,158 | 1,167 | |
| Expenses | 1,095 | 1,029 | 989 | 941 | 891 | 912 | 889 | 962 | 895 | 923 | 1,013 | 1,006 | 992 | |
| Operating Profit | -125 | 152 | 93 | 3 | 128 | 121 | 121 | 94 | 129 | 94 | 147 | 152 | 175 | |
| OPM % | -13% | 13% | 9% | 0.3% | 13% | 12% | 12% | 9% | 13% | 9% | 13% | 13% | 15% | |
| Other Income | 8 | -21 | 10 | 10 | 7 | 17 | 19 | 26 | 27 | 32 | 16 | 34 | 30 | |
| Interest | 12 | 14 | 12 | 12 | 13 | 12 | 5 | 5 | 23 | 23 | 24 | 24 | 25 | |
| Depreciation | 30 | 30 | 32 | 34 | 34 | 35 | 45 | 40 | 37 | 38 | 40 | 40 | 41 | |
| Profit before tax | -159 | 87 | 59 | -33 | 87 | 92 | 91 | 75 | 96 | 66 | 100 | 121 | 139 | |
| Tax % | 18% | 62% | -229% | 20% | 30% | 27% | 27% | -99% | 32% | 35% | 32% | 33% | 27% | |
| Net Profit | -187 | 33 | 195 | -39 | 61 | 67 | 66 | 150 | 65 | 43 | 68 | 81 | 101 | |
| EPS in Rs | -13.16 | 2.22 | 13.54 | -2.89 | 4.08 | 4.14 | 4.14 | 9.38 | 4.03 | 2.59 | 4.21 | 5.38 | 6.35 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202675.26%Promoter
Promoters75.26%
FIIs1.91%0.53
DIIs13.44%0.92
Public6.67%0.38
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,899.00 | 36.07 | 4,55,634 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,100.00 | 81.09 | 2,41,576 | 0.33% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,857.00 | 82.80 | 1,84,745 | 0.78% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| CIPLA | ₹1,385.00 | 31.26 | 1,11,888 | 0.94% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| ZYDUSLIFE | ₹1,120.00 | 22.95 | 1,11,720 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| LAURUSLABS | ₹1,840.00 | 90.93 | 99,417 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,110.00 | 16.20 | 96,483 | 0.85% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| AKUMS | ₹765.75 | 39.51 | 12,052 | 0.13% | 101 | +57.55% | 1,167 | +13.93% | 14.94% |
| Median: 158 Co. | ₹421.50 | 33.96 | 2,277 | 0.08% | 13 | +30.25% | 164 | +18.67% | 14.96% |
Filings
Annual reports2
Concall transcripts25
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026TranscriptFeb 2026PPTFeb 2026TranscriptNov 2025RECNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025RECAug 2025TranscriptJun 2025PPTJun 2025RECJun 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024TranscriptSep 2024PPTSep 2024RECSep 2024
Credit ratings6
Announcements5
ESG Rating 3 Sep - Akums received ESG rating of 65 for FY 2025-26 from NSE Sustainability on September 2, 2026.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 25 Aug - Akums will attend Ashwamedh–Elara India Dialogue 2026 on 2 September 2026 in Mumbai.Update On Schedule Of The Investors/Analysts Meet To Be Held On August 25, 2026 24 Aug - Akums cancels its August 25, 2026 investor meet with Antique Stock Broking due to medical reasons.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 13 AugAnnouncement under Regulation 30 (LODR)-Earnings Call Transcript 13 Aug - Transcript of Investors/Analysts conference call for the unaudited financial results of Q1 FY 27